Rekombinate virale und nichvirale Vektoren, die das Gen für den humanen Urokinase-Plasminogen-Aktivator enthalten, und ihre Verwenung bei der Behandlung verschiedener Arten von Leber-, Nieren-, Lungen-Pankreas- und Herzfibrose sowie hypertrophen Narben

摘要

The present invention encompasses a modified human urokinase plasminogen activator (“huPA”) gene, which was inserted in the adenoviral vector (pAd-.DELTA.huPA), which is not secreted and does not provoke hypercoagulation or spontaneous internal bleeding. It has been discovered that huPa induced a dramatic fibrosis reduction (85%) on day 10 of vector administration, compared to control cirrhotic rats and 55% hepatocyte proliferation increase. Liver function tests (ALT, AST, alkaline phosphatase and bilirubin) dropped to nearly normal levels and hepatocyte proliferation was observed. The invention also encompasses gene therapy with modified huPA to treat disorders in patients. In a particular embodiment, the invention encompasses a treatment for patients with liver cirrhosis.